Generation and Characterization of Torudokimab (LY3375880): A Monoclonal Antibody That Neutralizes Interleukin-33.
Angela J OkraglyKatie Brannon CorwinMarikka EliaDongmei HeOliver SchroederQing ZhangTatiyana ShiyanovaStuart BrightSarah B DickerLukasz ChlewickiStephanie M E TruhlarJulian DaviesChetan N PatelRobert J BenschopPublished in: Journal of inflammation research (2021)
Due to torudokimab's high affinity, its ability to completely neutralize IL-33 activity in vitro and in vivo, and the observed cynomolgus monkey pharmacokinetic properties, this molecule was selected for clinical development.
Keyphrases